|230.47|| -2.61 / -1.12%|
Allergan Plc engages in the research, development, and manufacture of pharmaceutical products. The firm offers products under the following brands: BOTOX, Juvederm, Linzess, Namenda, Restasis, Latisse, Teflaro, Lo Loestrin Fe, Bystolic, DORYX, Saphris, Fetzima, Namenda XR, Namzaric, Viberzi, Viibryd, Alphagan, LUMIGAN, ESTRACE Cream, Rapaflo, Asacol, DELZICOL, Zenpep, Avycaz, and Dalvance. Its brand portfolio delivers treatments that address unmet medical needs in therapeutic categories such as dermatology and aesthetics; central nervous system; eye care; women health and urology; gastroenterology and cystic fibrosis; and cardiovascular and infectious disease. The company was founded on October 1, 2012 and is headquartered in Dublin, Ireland.
|Brenton L. Saunders||President, Chief Executive Officer & Director|
|Robert A. Stewart||Chief Operating Officer|
|Maria Teresa Hilado||Chief Financial Officer|
|C. David Nicholson||Chief Research & Development Officer|
|Jonathon Kellerman||Global Chief Compliance Officer & Executive VP|